• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Adoptive cell therapy in multiple Myeloma
【24h】

Adoptive cell therapy in multiple Myeloma

机译：多发性细胞疗法在多个骨髓瘤中

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Recent breakthrough advances in Multiple Myeloma (MM) immunotherapy have been achieved with the approval of the first two monoclonal antibodies, elotuzumab and daratumumab. Adoptive cell therapy (ACT) represents yet another, maybe the most powerful modality of immunotherapy, in which allogeneic or autologous effector cells are expanded and activated ex vivo followed by their re-infusion back into patients. Infused effector cells belong to two categories: naturally occurring, non-engineered cells (donor lymphocyte infusion, myeloma infiltrating lymphocytes, deltagamma T cells) or genetically- engineered antigen-specific cells (chimeric antigen receptor T or NK cells, TCR-engineered cells).Areas covered: This review article summarizes our up-to-date knowledge on ACT in MM, its promises, and upcoming strategies to both overcome its toxicity and to integrate it into future treatment paradigms.Expert opinion: Early results of clinical studies using CAR T cells or TCR- engineered T cells in relapsed and refractory MM are particularly exciting, indicating the potential of long-term disease control or even cure. Despite several caveats including toxicity, costs and restricted availability in particular, these forms of immunotherapy are likely to once more revolutionize MM therapy.
机译：介绍：通过批准前两种单克隆抗体，ELOTuzumab和Daratumumab，已经实现了多种骨髓瘤（MM）免疫疗法的最近突破性突破。采用细胞疗法（ACT）代表另一个，也许是免疫疗法最强大的形态，其中异种或自体效应细胞被膨胀和活化，然后重新输注回患者。注入的效应细胞属于两类：天然存在，非工程细胞（供体淋巴细胞输注，骨髓瘤浸润淋巴细胞，Deltagamma T细胞）或遗传工程抗原特异性细胞（嵌合抗原受体T或NK细胞，TCR工程细胞） 。areas涵盖：这篇审查文章总结了我们的毫米行动，其承诺和即将到来的策略对克服毒性的最新知识，并将其整合到未来的治疗范式。普及意见：使用汽车的临床研究的早期结果T细胞或TCR-工程化的T细胞在复发和难发性mm中特别激动，表明长期疾病控制甚至固化的潜力。尽管有几种警告包括毒性，成本和限制的可用性，但这些形式的免疫疗法可能再次彻底改变MM疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号